Gynesonics, Inc's Sonata minimally invasive fibroid treatment is available to 50 million more lives than it was in 2019 now that the US Centers for Medicare and Medicaid Services (CMS) has established a code for the therapy, according to the California company.
“Bringing a breakthrough technology to the marketplace, we were not able to piggyback on an existing code for payment,” Gynesonics’ vice president of global commercialization, Rich Lanigan told Medtech Insight
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?